DVAX Dynavax Technologies Dashboard

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of novel vaccines and immuno-oncology therapeutics. The firm focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.

Company profile

Ticker

DVAX

Exchange

NASDAQ

Website

www.dynavax.com/

CEO

Ryan Spencer

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott ...

SEC CIK

0001029142

Corporate docs

Articles of Incorporation & Bylaws

IRS number

330728374

DVAX stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Valneva's COVID-19 Vaccine Candidate Using Dynavax's Adjuvant Shows Positive Interim Results

6 Apr 21

The Daily Biotech Pulse: Illumina Lights Up, Cara Soars On Index Inclusion, Novavax Starts Crossover Vaccine Study, Turning Point Data Readout

6 Apr 21

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 5)

Dynavax Announces Valneva SE Reported Results From Part A Of Phase 1/2 Trial Of Its COVID-19 Vaccine Using Dynavax's CpG 1018 Adjuvant; Valneva Plans To Commence Phase 3 Trial By End Of Apr.

6 Apr 21

Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Valneva SE reported positive initial results

The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping

24 Mar 21

Clover Biopharmaceuticals And Dynavax Announce First Participants Dosed In SPECTRA Global Phase 2/3 Clinical Trial For Adjuvanted S-Trimer COVID-19 Vaccine Candidate

24 Mar 21

Press releases

Pro users get this 30m faster

Positive Phase 1/2 Results for Valneva's Inactivated COVID-19 Vaccine Candidate Using Dynavax's CpG 1018™ Adjuvant

6 Apr 21

EMERYVILLE, Calif., April 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Valneva SE

Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001

6 Apr 21

VLA2001 was well tolerated with no safety concerns identified In the high dose group : IgG seroconversion rate of 100% Neutralizing antibody titres at or above levels generally seen in convalescent sera.

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 Apr 21

EMERYVILLE, Calif., April 2, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 142,000 shares of Dynavax common

Effective Diagnostics Help to Tame the Spread of the Pandemic

24 Mar 21

Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate

24 Mar 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

25 Feb 21

18 Apr 21

31 Dec 21

Financial summary

Financial statements Chart DVAX financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	32.31M	32.31M	32.31M	32.31M	32.31M	32.31M
Cash burn (monthly)	201.33K	649.17K	3.97M	5.7M	5.25M	7.69M
Cash used (since last report)	728.68K	2.35M	14.35M	20.62M	18.99M	27.82M
Cash remaining	31.58M	29.96M	17.96M	11.69M	13.32M	4.49M
Runway (months of cash)	156.9	46.2	4.5	2.1	2.5	0.6

Beta Read what these cash burn values mean

Recent insider trades

DVAX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
1 Apr 21	David F Novack	Common Stock	Sell	Dispose S	No	Yes	9.92	20,000	198.4K	117,399
12 Mar 21	Janssen Robert	Common Stock	Gift	Dispose G	No	No	0	1,000	0	86,861
2 Mar 21	Justin Burgess	Common Stock	Sell	Dispose S	No	No	8.82	1,165	10.28K	7,010
1 Mar 21	Kelly MacDonald	Stock Option Common Stock	Grant	Aquire A	No	No	8.9	350,000	3.12M	350,000
1 Mar 21	Justin Burgess	Common Stock	Sell	Dispose S	No	No	8.88	1,633	14.5K	8,175
1 Mar 21	Justin Burgess	Common Stock	Sell	Dispose S	No	No	8.88	1,325	11.77K	9,808
1 Mar 21	Justin Burgess	Common Stock	Option exercise	Aquire M	No	No	0	2,839	0	11,133
1 Mar 21	Justin Burgess	RSU Common Stock	Option exercise	Dispose M	No	No	0	2,839	0	0
26 Feb 21	Justin Burgess	Common Stock	Option exercise	Aquire M	No	No	0	3,906	0	8,294
26 Feb 21	Justin Burgess	Common Stock	Option exercise	Aquire M	No	No	0	3,167	0	4,388

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

DVAX institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

64.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	142	165	-13.9%
Opened positions	11	42	-73.8%
Closed positions	34	28	+21.4%
Increased positions	53	49	+8.2%
Reduced positions	43	40	+7.5%

13F shares	Current	Prev Q	Change
Total value	467.07M	877.07M	-46.7%
Total shares	73.21M	88.16M	-17.0%
Total puts	762.2K	842.2K	-9.5%
Total calls	568.3K	797.4K	-28.7%
Total put/call ratio	1.3	1.1	+27.0%

Largest owners	Shares	Value	Change
FHI Federated Hermes	11.95M	$53.16M	+9.1%
STT State Street	10.89M	$48.45M	-6.2%
BLK Blackrock	8.19M	$36.44M	+0.3%
Chicago Capital	5.78M	$25.73M	+47.1%
Vanguard	5.11M	$22.75M	-1.8%
Avidity Partners Management	4M	$17.8M	+97.5%
Partner Fund Management	2.94M	$13.07M	0.0%
Blair William & Co	2.18M	$9.72M	+7.2%
GS Goldman Sachs	2.03M	$9.06M	+168.4%
Rock Springs Capital Management	1.65M	$7.34M	+0.1%

Largest transactions	Shares	Bought/sold	Change
Bain Capital Life Sciences Investors	0	-10.9M	EXIT
Citadel Advisors	69.63K	-2.03M	-96.7%
Avidity Partners Management	4M	+1.98M	+97.5%
Chicago Capital	5.78M	+1.85M	+47.1%
Redmile	1.22M	-1.33M	-52.3%
GS Goldman Sachs	2.03M	+1.28M	+168.4%
Millennium Management	104.16K	-1.01M	-90.7%
FHI Federated Hermes	11.95M	+1M	+9.1%
Two Sigma Investments	425.69K	-872.02K	-67.2%
AMP Ameriprise Financial	1.32M	-788.57K	-37.5%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Pfizer • AMGEN • VBI Vaccines • VBI Vaccines • Celgene • Idera Pharmaceuticals • Astrazeneca • Roche • Novavax • Agenus

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: accuracy, acellular, alter, anesthesiologist, Assent, bargaining, Biden, BMGF, bond, booster, Brexit, bridge, broader, cancellation, capture, CEO, CEPI, cGMP, charitable, CHMP, Coalition, commerce, compliant, composition, compound, constitutionality, coupled, COVID, CPRA, creative, cutoff, cybersecurity, dedicate, differentially, diphtheria, disproportionate, distancing, drastically, driver, EEA, eighty, elderly, exacerbated, expiry, explained, exploit, factor, felt, fine, flu, forensic, forgivable, forgiven, Foundation, fundamental, GASC, gradually, half, harbor, harder, headwind, highlighted, Importantly, influenza, inJanuary, intensified, inter, Internationally, invoice, invoked, IPR, Israel, JUSTIN, Kingdom, labor, lawfully, leadership, length, lifted, Medicinal, Melinda, mix, Moderna, nationwide, nondiscriminatory, nurse, offsite, online, onsite, outpace, output, paradiso, paused, peter, PGR, pharmacy, philanthropic, phishing, phone, polarized, pose, posed, pre, predecessor, preferential, premier, promptly, proportion, proportional, punitive, question, reactogenicity, recession, reconsider, reliant, remote, remotely, reorder, repay, replenished, restoration, revealed, robust, Royal, scam, science, Scotland, sequester, seroprotection, shelter, Shield, shift, shifting, shipment, stall, stiff, strict, Supreme, Surefire, surety, survey, Switzerland, talent, Tdap, tender, tenure, tie, uninterrupted, unknown, unnecessary, unredacted, unrelated, unsecured, unusual, viable, video, virtual, visit, wholly, worsening

Removed: accommodate, allocable, arnold, attestation, autoimmune, bearing, broadening, charter, complaint, complying, david, declare, deployed, directed, Double, eliminating, generic, Helix, immunotherapy, implied, inflammatory, interference, invent, investigational, licensee, listed, lowering, MAA, necessarily, nominating, oncology, oronsky, outplacement, paragraph, pipeline, posted, PPACA, preceding, premium, print, PTO, retrospective, Trademark, Unaudited, writing

From filing 10-K 2020 FY